Relationships between EZH2 expression and EGFR mutation in lung adenocarcinoma
WANG Yuxin1, ZHAO Tianmiao2,BAO Fang3,HAN Yanhua4,KONG Lili5,and SUN Mei5
1.Department of Pathology, 2.Department of Facilities,3. Department of Military Healthcare,Jilin Provincial Corps Hospital of Chinese People’s Armed Police Force, Changchun 130052,China; 4. Training Base of Jilin Provincial Corps, Chinese People’s Armed Police Force, Changchun 130032,China; 5.Department of Pathology, Second Hospital of Jilin University, Changchun 130042,China
Abstract：Objective To explore the expression of EZH2 in lung adenocarcinoma and its associations with EGFR mutation.Methods Immunohistochemistry was used to examine the expression of EZH2 while EGFR mutation was detected with real-time fluorescence PCR.Results The expression of EZH2 in lung adenocarcinom(84.00%) was significantly higher than in normal lung tissues(12.00%) and in benign lung disease(11.11%) (P<0.05). EZH2 expression was related to tumor size, histological subtypes of adenocarcinoma and T stage(P<0.05), but not to EGFR mutation.Conclusion EZH2 may be involved in lung oncogenesis and development. The expression of EZH2 is not linked to EGFR mutation. It can be a new target for the treatment of lung adenocarcinoma.
Siegel R, Ma J, Zou Z, et al. Cancer statistics[J]. CA Cancer J Clin,2014,64(1):9-29.
[2]
Mok T S, Wu Y L, Thongprasert S, et al. Gefitinib or carboplatin paclitaxel in pulmonary adenocarcinoma[J]. N Engl J Med, 2009, 361(10):947-957
[3]
Cao R, Zhang Y. The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3[J]. Curr Opin Cenet Dev,2004,14(2):155-164.
[4]
Kondo Y, Shen L, Cheng A S, et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation[J]. Nat Genet, 2008,40(6):741-750.
[5]
Liu H H, Wang M Z, Hu K, et al. Research progress of the resistance mechanism of non-small cell lung cancer[J]. Chin J Lung Cancer, 2013,16(10):535-540
[6]
Takawa M, Masuda K. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker[J]. Cancer sci, 2011, 102(7):1298-1305.
[7]
Kikuchi J, Kinoshita I. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in non small cell lung cancers and their clinical and clinicopathologic significance[J]. Cancer, 2010, 116(12):3015-3024.
[8]
Hu Q, Ishikawa R. Enhancer of zeste homolog 2 is a novel prognostic biomarker in non small cell lung cancer[J]. Cancer, 2012, 118(6):1599-1606.
[9]
Wan L, Li X. Quantitative analysis of EZH2 expression and its correlations with lung cancer patients’ clinical pathological characteristics[J]. Clin Transl Oncol, 2013, 15(2):132-138.
[10]
Lv Y, Yuan C. The expression and significance of the enhancer of zeste homolog 2 in lung adenocarcinoma[J]. Oncol Rep, 2012, 28(1):147-154.
[11]
Behrens C, Solis L M. EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma[J]. Clin Cancer Res, 2013,19(23):6556-6565.
[12]
Takawa M, Masuda K. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker[J]. Cancer Sci, 2011, 102(7):1298-1305.
[13]
Zhang J L, Su X L, Yan M R,et al . The effect of cell proliferation and migration by short hairpin RNA interference EZH2 expression in human lung cancer cell line[J]. Chen J Clinicians, 2011, 5(20):5871-5874.
[14]
Zhang J G, Guo J F. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2[J]. J thoracic Oncol,2011,6(4):671-178.
[15]
Xia H, Yu C H. EZH2 silencing with RNi enhances irradiation-induced inhibition of human lung cancer growth in vitro and in vivo[J]. Oncol lett, 2012, 4(1):135-140.
[16]
Fillmore C M, Xu C. EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors[J]. Nature, 2015, 520(7546):239-242.
2017, Vol. 28 
